Please login to the form below

Not currently logged in

Whatever happened to long agency lunches?

Digital communication may be simpler, but is it the best way to do business?

For starters
I went for a drink in my local on Monday after work and bumped into a couple of industry marketers, one of whom has been playing email tag with me because he has found himself too booked up, with too many random meetings to take time out to discuss the development of his campaign. 

We sat and chatted over a drink for an hour and now have the wheels in motion for campaign development and the bones of a direct to consumer (DTC) communication platform. The other one bought me a drink, we had a chat about digital projects, a proposal we are now working on, and I had to get a taxi home! 

The main
The point I'm trying to make is that doing business over a drink or a meal is a ritual that has existed for centuries. Taking clients to breakfast, lunch or dinner has long been an effective way to build relationships and often culminates in great creative ideas and innovations. 

Giving yourself time out in a relaxed atmosphere unleashes your creative juices, but the modern pharma work ethic has changed so much during the past decade that people now just tend to grab an inedible snack and a muddy machine coffee while rushing from one meeting to the next. 

The need to fill every day with meetings and actions from meetings, which never get actioned because you're too busy in meetings, is surely counter-productive?

The emphasis on being busy is so high, but being busy doesn't necessarily make you more productive, and certainly not more creative. When you're busy, your attention is on the moment, with no time to contemplate or consider the opportunities around you.

Sweet temptation
The motive for big pharma mergers and acquisitions, and multinational agency networks, is to develop business and make more profit by achieving economies of scale. However, cutting costs by homogenising everything doesn't always pay dividends. When everything is focused on the bottom line, tunnel vision sets in, and all too often great creativity flies out of the window.

Digital communication has made everything accessible at the touch of a keypad. We don't even have to get out of bed in the morning to send our first email, but is this really the best way to do business? 

Yes, emailing is a lot less costly and much quicker than having to travel, walk into the next office or chat across the desk and spend valued time with each other, but the end point is a poorer idea, because ideas arise from human interaction and considered thought. And all of us – creative agencies and pharma marketers – are in the ideas business. 

To end
Have a think about the moments in your life when you've had the best ideas and they will probably have come to you at the most unexpected times, when your mind is clear. 

Mainly when you are relaxed and out of the work zone. Maybe over a drink in the evening, having a long soak in the bath, or a stroll with the dog. 

Those thoughts would have been stifled in the day-to-day mayhem that prevails in our industry. So in our information-rich and time-poor lives, let's all try to take some valuable time out... Anyone for lunch?

The Author
Juliet La Marque
is managing director at Life

1st July 2011


COVID-19 Updates and Daily News

Featured jobs


Add my company

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...